Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 23.42 USD -3.7% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Intrinsic Value

BCYC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BCYC stock under the Base Case scenario is 11.86 USD. Compared to the current market price of 23.42 USD, Bicycle Therapeutics PLC is Overvalued by 49%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BCYC Intrinsic Value
11.86 USD
Overvaluation 49%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bicycle Therapeutics PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BCYC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BCYC?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Bicycle Therapeutics PLC

Provide an overview of the primary business activities
of Bicycle Therapeutics PLC.

What unique competitive advantages
does Bicycle Therapeutics PLC hold over its rivals?

What risks and challenges
does Bicycle Therapeutics PLC face in the near future?

Has there been any significant insider trading activity
in Bicycle Therapeutics PLC recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bicycle Therapeutics PLC.

Provide P/S
for Bicycle Therapeutics PLC.

Provide P/E
for Bicycle Therapeutics PLC.

Provide P/OCF
for Bicycle Therapeutics PLC.

Provide P/FCFE
for Bicycle Therapeutics PLC.

Provide P/B
for Bicycle Therapeutics PLC.

Provide EV/S
for Bicycle Therapeutics PLC.

Provide EV/GP
for Bicycle Therapeutics PLC.

Provide EV/EBITDA
for Bicycle Therapeutics PLC.

Provide EV/EBIT
for Bicycle Therapeutics PLC.

Provide EV/OCF
for Bicycle Therapeutics PLC.

Provide EV/FCFF
for Bicycle Therapeutics PLC.

Provide EV/IC
for Bicycle Therapeutics PLC.

Show me price targets
for Bicycle Therapeutics PLC made by professional analysts.

What are the Revenue projections
for Bicycle Therapeutics PLC?

How accurate were the past Revenue estimates
for Bicycle Therapeutics PLC?

What are the Net Income projections
for Bicycle Therapeutics PLC?

How accurate were the past Net Income estimates
for Bicycle Therapeutics PLC?

What are the EPS projections
for Bicycle Therapeutics PLC?

How accurate were the past EPS estimates
for Bicycle Therapeutics PLC?

What are the EBIT projections
for Bicycle Therapeutics PLC?

How accurate were the past EBIT estimates
for Bicycle Therapeutics PLC?

Compare the revenue forecasts
for Bicycle Therapeutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bicycle Therapeutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bicycle Therapeutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bicycle Therapeutics PLC compared to its peers.

Compare the P/E ratios
of Bicycle Therapeutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Bicycle Therapeutics PLC with its peers.

Analyze the financial leverage
of Bicycle Therapeutics PLC compared to its main competitors.

Show all profitability ratios
for Bicycle Therapeutics PLC.

Provide ROE
for Bicycle Therapeutics PLC.

Provide ROA
for Bicycle Therapeutics PLC.

Provide ROIC
for Bicycle Therapeutics PLC.

Provide ROCE
for Bicycle Therapeutics PLC.

Provide Gross Margin
for Bicycle Therapeutics PLC.

Provide Operating Margin
for Bicycle Therapeutics PLC.

Provide Net Margin
for Bicycle Therapeutics PLC.

Provide FCF Margin
for Bicycle Therapeutics PLC.

Show all solvency ratios
for Bicycle Therapeutics PLC.

Provide D/E Ratio
for Bicycle Therapeutics PLC.

Provide D/A Ratio
for Bicycle Therapeutics PLC.

Provide Interest Coverage Ratio
for Bicycle Therapeutics PLC.

Provide Altman Z-Score Ratio
for Bicycle Therapeutics PLC.

Provide Quick Ratio
for Bicycle Therapeutics PLC.

Provide Current Ratio
for Bicycle Therapeutics PLC.

Provide Cash Ratio
for Bicycle Therapeutics PLC.

What is the historical Revenue growth
over the last 5 years for Bicycle Therapeutics PLC?

What is the historical Net Income growth
over the last 5 years for Bicycle Therapeutics PLC?

What is the current Free Cash Flow
of Bicycle Therapeutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bicycle Therapeutics PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bicycle Therapeutics PLC

Current Assets 966.2m
Cash & Short-Term Investments 890.9m
Receivables 58m
Other Current Assets 17.4m
Non-Current Assets 30.6m
PP&E 20.6m
Other Non-Current Assets 9.9m
Current Liabilities 56.4m
Accounts Payable 5.7m
Accrued Liabilities 38.7m
Other Current Liabilities 12m
Non-Current Liabilities 109.3m
Other Non-Current Liabilities 109.3m
Efficiency

Earnings Waterfall
Bicycle Therapeutics PLC

Revenue
36.9m USD
Operating Expenses
-233.4m USD
Operating Income
-196.5m USD
Other Expenses
30.2m USD
Net Income
-166.3m USD

Free Cash Flow Analysis
Bicycle Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BCYC Profitability Score
Profitability Due Diligence

Bicycle Therapeutics PLC's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
31/100
Profitability
Score

Bicycle Therapeutics PLC's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

BCYC Solvency Score
Solvency Due Diligence

Bicycle Therapeutics PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
65/100
Solvency
Score

Bicycle Therapeutics PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCYC Price Targets Summary
Bicycle Therapeutics PLC

Wall Street analysts forecast BCYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCYC is 40.06 USD with a low forecast of 28.28 USD and a high forecast of 58.8 USD.

Lowest
Price Target
28.28 USD
21% Upside
Average
Price Target
40.06 USD
71% Upside
Highest
Price Target
58.8 USD
151% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BCYC?

Click here to dive deeper.

Dividends

Bicycle Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for BCYC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BCYC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

1.6B USD

Dividend Yield

0%

Description

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.

Contact

CAMBRIDGESHIRE
Cambridge
Babraham Hall
+11441223261503.0
www.bicycletherapeutics.com

IPO

2019-05-23

Employees

119

Officers

CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
Co-Founder & Non-Executive Director
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE
Chief Financial Officer
Ms. Alethia Rene Young
Chief Development Officer
Dr. Santiago Arroyo M.D., Ph.D.
Scientific Founder
Dr. Christian Heinis
Chief Operating Officer
Mr. Alistair Milnes
Show More
Senior VP, Chief Accounting Officer & Principal Accounting Officer
Mr. Travis Thompson
Chief Technology Officer
Dr. Michael Skynner B.sc. Ph.d., Ph.D.
Senior Vice President of Investor Relations and Corporate Communications
Ms. Stephanie Yao
General Counsel
Mr. Zafar Qadir
Show Less

See Also

Discover More
What is the Intrinsic Value of one BCYC stock?

The intrinsic value of one BCYC stock under the Base Case scenario is 11.86 USD.

Is BCYC stock undervalued or overvalued?

Compared to the current market price of 23.42 USD, Bicycle Therapeutics PLC is Overvalued by 49%.

Back to Top